Background: Cardiac troponin T (cTnT) is used as a biomarker of myocardial damage for the diagnosis of acute myocardial infarction and acute coronary syndrome. The aim was to investigate the association between advanced glycation end products (AGEs) and cTnT in hemodialysis (HD) patients. Methods: The plasma level of cTnT in 224 HD patients was measured using the electrochemiluminescence immunoassay. The plasma levels of NΕ-(carboxymethyl)lysine (CML) and pentosidine were measured using an enzyme-linked immunosorbent assay. Results: The cTnT-positive group (>0.1 ng/ml) showed significantly high plasma levels of calcium, CML and pentosidine as compared with the cTnT-negative group. In multiple logistic regression analysis, the prevalence of patients with high plasma calcium (>median) was increased in the cTnT-positive group as compared with the cTnT-negative group (OR: 5.08, 95% CI: 1.62–15.92, p < 0.01). The prevalence of high plasma CML (>median) was increased in the cTnT-positive group (OR: 4.45, 95% CI: 1.41–14.03, p < 0.05). Further, the prevalence of high plasma pentosidine (>median) was also increased in the cTnT-positive group (OR: 4.94, 95% CI: 1.55–15.70, p < 0.01). Conclusion: In addition to calcium, AGEs such as CML and pentosidine were associated with cTnT, a marker of myocardial damage, in HD patients.

Keywords:
Advanced glycation end products, Pentosidine, Cardiac troponin T, Nε-(carboxymethyl)lysine, Myocardial damage, Hemodialysis
1.
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112–S119.
2.
Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T: Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of advanced glycation endproducts, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999;19:325–333.
3.
Fishbane S: Cardiovascular risk evaluation before kidney transplantation. J Am Soc Nephrol 2005;16:843–845.
4.
Clyne N, Lins LE, Pehrsson SK: Occurrence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol 1986;20:307–311.
5.
Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 1993;16:31–36.
6.
Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984;25:653–659.
7.
Ikram H, Lynn KL, Bailey RR, Little PJ: Cardiovascular changes in chronic hemodialysis patients. Kidney Int 1983;24:371–376.
8.
Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223–234.
9.
Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D, Marinari UM: Relationships between glycation and oxidation related fluorescence in rat collagen during aging: an in vivo and in vitro study. Lab Invest 1994;70:61–67.
10.
Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA: Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992;41(Suppl 2):36–41.
11.
Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al: Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994;343:1519–1522.
12.
Dawnay A, Millar DJ: The pathogenesis and consequences ofAGE formation in uraemia and its treatment: Cell Mol Biol 1998;44:1081–1094.
13.
Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000;57:2571–2585.
14.
Lamb EJ, Webb MC, Abbas NA: The significance of serum troponin T in patients with kidney disease: a review of the literature. Ann Clin Biochem 2004;41:1–9.
15.
Wood GN, Keevil B, Gupta J, Foley R, Bubtana A, McDowell G, Ackrill P: Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. Nephrol Dial Transplant 2003;18:1610–1615.
16.
Ammann P, Pfisterer M, Fehr T, Rickli H: Raised cardiac troponins. BMJ 2004;328:1028–1029.
17.
Ooi DS, Zimmerman D, Graham J, Wells GA: Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 2001;47:412–417.
18.
Dierkes K, Domrose U, Westphal S: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000;102:1964–1969.
19.
Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002;40:68–75.
20.
Taki K, Takayama F, Tsuruta Y, Niwa T: Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006;70:218–224.
21.
Meng J, Sakata N, Imanaga Y, Takebayashi S, Nagai R, Horiuchi S: Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: relevance to glycoxidation damage. Nephron 2001;88:30–35.
22.
Miyata T, Ueda Y, Saito A, Kurokawa K: ‘Carbonyl stress’ and dialysis-related amyloidosis. Nephrol Dial Transplant 2000;15 (Suppl):125–128.
23.
Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I: High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007;13:199–206.
24.
Kitauchi T, Yoshida K, Yoneda T, Saka T, Yoshikawa M, Ozono S, Hirao Y: Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol 2004;8:48–53.
25.
Baidoshvili A, Niessen HW, Stooker W, Huybregts RA, Hack CE, Rauwerda JA, Meijer CJ, Eijsman L, van Hinsbergh VW, Schalkwijk CG: Nε-(Carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis 2004;174:287–292.
26.
Takayama F, Miyazaki S, Morita T, Hirasawa Y, Niwa T: Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Kidney Int 2001;78:S172–S176.
27.
Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I, Schinzel R, Czeslik E, Silber RE, Scheubel RJ: Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 2007;42:668–675.
28.
Apple FS, Murakami MM, Pearce LA, Herzog CA: Predictive value of cardiac troponin I and T for subsequent death in endstage renal disease. Circulation 2002;106:2941–2945.
29.
Fredericks S, Murray JF, Bewick M, Chang R, Collinson PO, Carter ND, Holt DW: Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. Clin Chem 2001;47:1023–1030.
30.
Klein G, Kampmann M, Baum H, Rauscher T, Vukovic T, Hallermayer K, Rehner H, Muller-Bardorff M, Katus HA: Clinical performance of the new cardiac markers Troponin T and CK-MB on the Elecsys 2010. Wien Klin Wochenschr 1998;110(Suppl 3):40–51.
31.
Jung HH, Ma KR, Han H: Elevated concentrations of cardiac troponins are associated with severe coronary artery calcification in asymptomatic haemodialysis patients. Nephrol Dial Transplant 2004;19:3117–3123.
32.
Yoshida S, Yamada K, Hamaguchi K, Nishimura M, Hatakeyama E, Tsuchida H, Sakamoto K, Kashiwabara H, Yokoyama T, Ikeda K, Horiuchi S: Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 1998;49:273–280.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.